KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Cash: 2016-2024

Historic Change in Cash for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$999.0 million.

  • Moderna's Change in Cash rose 82.35% to -$147.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$513.0 million, marking a year-over-year increase of 60.72%. This contributed to the annual value of -$999.0 million for FY2024, which is 245.67% down from last year.
  • As of FY2024, Moderna's Change in Cash stood at -$999.0 million, which was down 245.67% from -$289.0 million recorded in FY2023.
  • Moderna's Change in Cash's 5-year high stood at $4.2 billion during FY2021, with a 5-year trough of -$3.6 billion in FY2022.
  • For the 3-year period, Moderna's Change in Cash averaged around -$1.6 billion, with its median value being -$999.0 million (2024).
  • In the last 5 years, Moderna's Change in Cash surged by 665.88% in 2020 and then plummeted by 245.67% in 2024.
  • Over the past 5 years, Moderna's Change in Cash (Yearly) stood at $2.4 billion in 2020, then soared by 76.88% to $4.2 billion in 2021, then tumbled by 186.25% to -$3.6 billion in 2022, then skyrocketed by 92.07% to -$289.0 million in 2023, then plummeted by 245.67% to -$999.0 million in 2024.